Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 40

1.

Impact of Nivolumab versus Docetaxel on Health-Related Quality of Life and Symptoms in Patients with Advanced Squamous Non-Small Cell Lung Cancer: Results from the CheckMate 017 Study.

Reck M, Taylor F, Penrod JR, DeRosa M, Morrissey L, Dastani H, Orsini L, Gralla RJ.

J Thorac Oncol. 2018 Feb;13(2):194-204. doi: 10.1016/j.jtho.2017.10.029. Epub 2017 Nov 10.

PMID:
29129758
2.

The Humanistic Burden of Small Cell Lung Cancer (SCLC): A Systematic Review of Health-Related Quality of Life (HRQoL) Literature.

Bennett BM, Wells JR, Panter C, Yuan Y, Penrod JR.

Front Pharmacol. 2017 Jun 15;8:339. doi: 10.3389/fphar.2017.00339. eCollection 2017. Review.

3.

P2.46 (also presented as PD1.01): LCSS as a Marker of Treatment Benefit With Nivolumab vs Docetaxel in Pts With Advanced Non-Squamous NSCLC From Checkmate 057: Track: Immunotherapy.

Gralla RJ, Spigel D, Bennett B, Taylor F, Penrod JR, Derosa M, Dastani H, Orsini L, Mathias C, Reck M.

J Thorac Oncol. 2016 Oct;11(10S):S247. doi: 10.1016/j.jtho.2016.08.117. Epub 2016 Sep 22. No abstract available.

4.

PD1.01 (also presented as P2.46): LCSS as a Marker of Treatment Benefit With Nivolumab vs Docetaxel in Pts With Advanced Non-Squamous NSCLC From Checkmate 057.

Gralla RJ, Spigel D, Bennett B, Taylor F, Penrod JR, Derosa M, Dastani H, Orsini L, Mathias C, Reck M.

J Thorac Oncol. 2016 Oct;11(10S):S171. doi: 10.1016/j.jtho.2016.08.009. Epub 2016 Sep 22. No abstract available.

5.

Lost Labor Productivity Costs of Prostate Cancer to Patients and Their Spouses: Evidence From US National Survey Data.

Rizzo JA, Zyczynski TM, Chen J, Mallow PJ, Trudel GC, Penrod JR.

J Occup Environ Med. 2016 Apr;58(4):351-8. doi: 10.1097/JOM.0000000000000621.

PMID:
27058474
6.

Economic evaluation of nivolumab for the treatment of second-line advanced squamous NSCLC in Canada: a comparison of modeling approaches to estimate and extrapolate survival outcomes.

Goeree R, Villeneuve J, Goeree J, Penrod JR, Orsini L, Tahami Monfared AA.

J Med Econ. 2016 Jun;19(6):630-44. doi: 10.3111/13696998.2016.1151432. Epub 2016 Mar 1.

PMID:
26850122
7.

Resource Utilization Among Advanced Squamous and non-Squamous non-Small Cell Lung Cancer Patients Receiving Second-Line Treatment in France, Germany, Italy, and Spain: Results of A Retrospective Medical Chart Review.

Solem CT, Penrod JR, Lees M, Manley Daumont M, Macahilig CP, Baeten S, Verleger K, Wilke T.

Value Health. 2015 Nov;18(7):A450. doi: 10.1016/j.jval.2015.09.1133. Epub 2015 Oct 20. No abstract available.

8.

Caring for relatives with lung cancer in Europe: an evaluation of caregivers' experience.

Jassem J, Penrod JR, Goren A, Gilloteau I.

Qual Life Res. 2015 Dec;24(12):2843-52. doi: 10.1007/s11136-015-1028-1. Epub 2015 Jun 12.

PMID:
26068731
9.

The option value of innovative treatments in the context of chronic myeloid leukemia.

Sanchez Y, Penrod JR, Qiu XL, Romley J, Thornton Snider J, Philipson T.

Am J Manag Care. 2012 Nov;18(11 Suppl):S265-71.

10.

Value of survival gains in chronic myeloid leukemia.

Yin W, Penrod JR, Maclean R, Lakdawalla DN, Philipson T.

Am J Manag Care. 2012 Nov;18(11 Suppl):S257-64.

11.

Dynamic cost-effectiveness of oncology drugs.

Lu Y, Penrod JR, Sood N, Woodby S, Philipson T.

Am J Manag Care. 2012 Nov;18(11 Suppl):S249-56.

12.

Ipilimumab in 2nd line treatment of patients with advanced melanoma: a cost-effectiveness analysis.

Barzey V, Atkins MB, Garrison LP, Asukai Y, Kotapati S, Penrod JR.

J Med Econ. 2013;16(2):202-12. doi: 10.3111/13696998.2012.739226. Epub 2012 Nov 1. Erratum in: J Med Econ. 2013;16(2):212.

PMID:
23057750
13.

Patients value metastatic cancer therapy more highly than is typically shown through traditional estimates.

Seabury SA, Goldman DP, Maclean JR, Penrod JR, Lakdawalla DN.

Health Aff (Millwood). 2012 Apr;31(4):691-9. doi: 10.1377/hlthaff.2012.0174.

PMID:
22492885
14.

Survey results show that adults are willing to pay higher insurance premiums for generous coverage of specialty drugs.

Romley JA, Sanchez Y, Penrod JR, Goldman DP.

Health Aff (Millwood). 2012 Apr;31(4):683-90. doi: 10.1377/hlthaff.2011.1301.

PMID:
22492884
15.

How cancer patients value hope and the implications for cost-effectiveness assessments of high-cost cancer therapies.

Lakdawalla DN, Romley JA, Sanchez Y, Maclean JR, Penrod JR, Philipson T.

Health Aff (Millwood). 2012 Apr;31(4):676-82. doi: 10.1377/hlthaff.2011.1300.

PMID:
22492883
16.

Indirect comparison of the efficacy of cetuximab and cisplatin in squamous cell carcinoma of the head and neck.

Levy AR, Johnston KM, Sambrook J, Donato B, Penrod JR, Corral M, Chasen M.

Curr Med Res Opin. 2011 Dec;27(12):2253-9. doi: 10.1185/03007995.2011.633989. Epub 2011 Nov 14. Review.

PMID:
22017232
17.

Retrospective evaluation of cetuximab-related adverse events from claims databases--methodological concerns.

Maier S, Peltz G, Penrod JR, Sugarman KP.

Ann Oncol. 2010 Aug;21(8):1731-2; author reply 1732-3. doi: 10.1093/annonc/mdq327. Epub 2010 Jul 6. No abstract available.

PMID:
20605932
18.

Gestational diabetes mellitus screening and diagnosis: a prospective randomised controlled trial comparing costs of one-step and two-step methods.

Meltzer SJ, Snyder J, Penrod JR, Nudi M, Morin L.

BJOG. 2010 Mar;117(4):407-15. doi: 10.1111/j.1471-0528.2009.02475.x. Epub 2010 Jan 26.

19.

Effects of home-based pulmonary rehabilitation in patients with chronic obstructive pulmonary disease: a randomized trial.

Maltais F, Bourbeau J, Shapiro S, Lacasse Y, Perrault H, Baltzan M, Hernandez P, Rouleau M, Julien M, Parenteau S, Paradis B, Levy RD, Camp P, Lecours R, Audet R, Hutton B, Penrod JR, Picard D, Bernard S; Chronic Obstructive Pulmonary Disease Axis of Respiratory Health Network, Fonds de recherche en santé du Québec.

Ann Intern Med. 2008 Dec 16;149(12):869-78.

PMID:
19075206
20.

Implant overdentures for edentulous elders: study of patient preference.

Esfandiari S, Lund JP, Penrod JR, Savard A, Thomason JM, Feine JS.

Gerodontology. 2009 Mar;26(1):3-10. doi: 10.1111/j.1741-2358.2008.00237.x. Epub 2008 May 20.

PMID:
18498362
21.

Comparing invasive and noninvasive management strategies for acute myocardial infarction using administrative databases.

Pilote L, Beck CA, Eisenberg MJ, Humphries K, Joseph L, Penrod JR, Tu JV.

Am Heart J. 2008 Jan;155(1):42-8.

PMID:
18082487
22.

Costs of rheumatoid arthritis: new estimates from the human capital method and comparison to the willingness-to-pay method.

Fautrel B, Clarke AE, Guillemin F, Adam V, St-Pierre Y, Panaritis T, Fortin PR, Menard HA, Donaldson C, Penrod JR.

Med Decis Making. 2007 Mar-Apr;27(2):138-50.

PMID:
17409364
23.

The systemic lupus erythematosus Tri-Nation study: cumulative indirect costs.

Panopalis P, Petri M, Manzi S, Isenberg DA, Gordon C, Senécal JL, Penrod JR, Joseph L, St Pierre Y, Pineau C, Fortin PR, Sutcliffe N, Goulet JR, Choquette D, Grodzicky T, Esdaile JM, Clarke AE; Tri-Nation Study Group.

Arthritis Rheum. 2007 Feb 15;57(1):64-70.

24.

Cost-effectiveness of highly active antiretroviral therapy in South Africa.

Badri M, Maartens G, Mandalia S, Bekker LG, Penrod JR, Platt RW, Wood R, Beck EJ.

PLoS Med. 2006 Jan;3(1):e4. Epub 2005 Dec 6.

25.

Use of complementary and alternative therapies by patients with self-reported chronic back pain: a nationwide survey in Canada.

Foltz V, St Pierre Y, Rozenberg S, Rossignol M, Bourgeois P, Joseph L, Adam V, Penrod JR, Clarke AE, Fautrel B.

Joint Bone Spine. 2005 Dec;72(6):571-7. Epub 2005 Sep 7.

PMID:
16256395
26.

A cost-effectiveness and cost-utility study of lung transplantation.

Vasiliadis HM, Collet JP, Penrod JR, Ferraro P, Poirier C.

J Heart Lung Transplant. 2005 Sep;24(9):1275-83.

PMID:
16143245
27.

Cost-effectiveness of mandibular two-implant overdentures and conventional dentures in the edentulous elderly.

Heydecke G, Penrod JR, Takanashi Y, Lund JP, Feine JS, Thomason JM.

J Dent Res. 2005 Sep;84(9):794-9.

PMID:
16109986
28.

A Canadian, multicentre, randomized clinical trial of home-based pulmonary rehabilitation in chronic obstructive pulmonary disease: rationale and methods.

Maltais F, Bourbeau J, Lacasse Y, Shapiro S, Perrault H, Penrod JR, Baltzan M, Rouleau M, Julien M, Paradis B, Audet R, Hernandez P, Levy RD, Camp P, Lecours R, Picard D, Bernard S.

Can Respir J. 2005 May-Jun;12(4):193-8.

PMID:
16003455
29.

The systemic lupus erythematosus tri-nation study: longitudinal changes in physical and mental well-being.

Panopalis P, Petri M, Manzi S, Isenberg DA, Gordon C, Senecal JL, Penrod JR, Joseph L, St Pierre Y, Pineau C, Fortin PR, Sutcliffe N, Goulet JR, Choquette D, Grodzicky T, Esdaile JM, Clarke AE.

Rheumatology (Oxford). 2005 Jun;44(6):751-5. Epub 2005 Mar 9.

PMID:
15757968
30.

Valuing a hypothetical cure for rheumatoid arthritis using the contingent valuation methodology: the patient perspective.

Fautrel B, Clarke AE, Guillemin F, Adam V, St-Pierre Y, Panaritis T, Fortin PR, Menard HA, Donaldson C, Penrod JR.

J Rheumatol. 2005 Mar;32(3):443-53.

PMID:
15742435
31.

Co-morbidity and physician use in fibromyalgia.

Bernatsky S, Dobkin PL, De Civita M, Penrod JR.

Swiss Med Wkly. 2005 Feb 5;135(5-6):76-81.

PMID:
15729611
32.

What is the impact of adolescent arthritis and rheumatism? Evidence from a national sample of Canadians.

Adam V, St-Pierre Y, Fautrel B, Clarke AE, Duffy CM, Penrod JR.

J Rheumatol. 2005 Feb;32(2):354-61.

PMID:
15693099
33.

Costs of workups for the diagnosis of early arthritis: results of a nationwide survey.

Fautrel B, Saraux A, Maillefert JF, Kaye O, Lafforgue P, Flipo RM, Penrod JR, Guillemin F; Club Rhumatisme & Inflammation of the the French Society for Rheumatology.

Arthritis Rheum. 2004 Aug 15;51(4):507-12.

34.

Health services costs and their determinants in women with fibromyalgia.

Penrod JR, Bernatsky S, Adam V, Baron M, Dayan N, Dobkin PL.

J Rheumatol. 2004 Jul;31(7):1391-8.

PMID:
15229962
35.

A cost comparison of mandibular two-implant overdenture and conventional denture treatment.

Takanashi Y, Penrod JR, Lund JP, Feine JS.

Int J Prosthodont. 2004 Mar-Apr;17(2):181-6.

PMID:
15119869
36.

Surgical placement of two implants in the anterior edentulous mandible--how much time does it take?

Takanashi Y, Penrod JR, Chehade A, Klemetti E, Lund JP, Feine JS.

Clin Oral Implants Res. 2003 Apr;14(2):188-92.

PMID:
12656878
37.

Timing of total joint replacement affects clinical outcomes among patients with osteoarthritis of the hip or knee.

Fortin PR, Penrod JR, Clarke AE, St-Pierre Y, Joseph L, Bélisle P, Liang MH, Ferland D, Phillips CB, Mahomed N, Tanzer M, Sledge C, Fossel AH, Katz JN.

Arthritis Rheum. 2002 Dec;46(12):3327-30.

38.

Use of complementary and alternative therapies by patients self-reporting arthritis or rheumatism: results from a nationwide canadian survey.

Fautrel B, Adam V, St-Pierre Y, Joseph L, Clarke AE, Penrod JR.

J Rheumatol. 2002 Nov;29(11):2435-41.

PMID:
12415605
39.

Does a prosthodontist spend more time providing mandibular two-implant overdentures than conventional dentures?

Takanashi Y, Penrod JR, Chehade A, Klemetti E, Savard A, Lund JP, Feine JS.

Int J Prosthodont. 2002 Jul-Aug;15(4):397-403.

PMID:
12170856
40.

Supplemental Content

Loading ...
Support Center